Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort studyMarie Kostine, Thierry Schaeverbeke, M. Beylot‐Barry et al.|Annals of the Rheumatic Diseases|2017Cited by 302
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Thierry Schaeverbeke, M. Beylot‐Barry et al.|European Journal of Cancer|2021Cited by 93
OP0088 Immune-related adverse events of cancer immunotherapy – when inflammatory side effects are associated with survival: a single-centre prospective cohort studyMarie Kostine, Thierry Schaeverbeke, M. Beylot‐Barry et al.|Annals of the Rheumatic Diseases|2018Cited by 2
FRI0584 Rheumatic and musculoskeletal disorders related to immune checkpoint inhibitors in cancer patients: a prospective single-institution studyKhaled marie, Thierry Schaeverbeke, L. Rouxel et al.|Annals of the Rheumatic Diseases|2017Cited by 1
OP0336 COMMONLY USED DRUGS IN RHEUMATOLOGY MAY ALTER ANTI-TUMORAL RESPONSE TO IMMUNE CHECKPOINT INHIBITORSMarie Kostine, Thierry Schaeverbeke, M. Beylot‐Barry et al.|Annals of the Rheumatic Diseases|2019Cited by 1